A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

drug protocol number

RVX222-CS-025

drug sponsor

Resverlogics Corp / Balsam

drug study

Apabetalone

drug trial site

King Abdulaziz Medical City NG (Al-Ahsa), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase